Babyl & Novo Nordisk partner to provide an innovative approach to diabetes awareness and care in Rwanda
Retrieved on:
Thursday, December 1, 2022
General Health, Diabetes, Health, Health Technology, Telemedicine, Virtual Medicine, Privacy, Patient, AI, Blood, Disease management, Conditional sentence, Novo Nordisk, Partnership, Government, Nursing, Diabetes, Medicare, NYSE, Integration, RSSB, Health, Digital technology, NHS, Obesity, Health insurance, Pharmaceutical industry, Medicaid, Britam Holdings
Babyl, a subsidiary of Babylon (NYSE: BBLN), and Novo Nordisk announced today that they have entered an innovative partnership to contribute to the expansion of diabetes awareness and care in Rwanda.
Key Points:
- Babyl, a subsidiary of Babylon (NYSE: BBLN), and Novo Nordisk announced today that they have entered an innovative partnership to contribute to the expansion of diabetes awareness and care in Rwanda.
- To support the initiative, Babyl will be rolling out a training scheme for clinicians to digitally provide diabetes care for patients, drawing on Novo Nordisks global expertise and best practices.
- This increased capacity of health providers to screen and manage diabetes cases will help Babyl to provide patients with effective and consistent care.
- We are so excited about this cutting edge partnership with Novo Nordisk that allows Babyl to strengthen our offering to patients and raise awareness of diabetes.